Attosecond pulses enable sub-femtosecond studies of ultrafast electron dynamics. Since 2001, pulse durations have shortened ...
SHANNON, CLARE, IRELAND, February 27, 2026 /EINPresswire.com/ -- Announcing a new publication from Opto-Electronic ...
Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...
Why do premenopausal women face lower hypertension risk? Estrogen may protect blood pressure by relaxing blood vessels and ...
Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. | Kyowa ...
The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...
Namodenoson (CF102), an investigational small-molecule A3 adenosine receptor (A3AR) agonist, has demonstrated favorable ...
Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected ...
CNP-104 improved key cholestasis endpoints at one year, including a composite serum alkaline phosphatase (ALP) and bilirubin biochemical ...
Fecal microbiota transplants may enhance patients’ response to immunotherapy, but experts caution that the latest data remain proof-of-concept and far from practice-changing.
The recent safety update led Kyowa Kirin and Amgen to conclude potential risks may outweigh benefits for patient populations.
As part of its launch, Persevere has acquired the clinical-stage program and related assets for misetionamide (GP-2250) from Geistlich Pharma AG. Misetionamide is a novel, first-in-class dual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results